Workflow
Lipocine(LPCN) - 2024 Q3 - Quarterly Report
LPCNLipocine(LPCN)2024-11-07 11:09

Product Development and Licensing - TLANDO received FDA approval on March 28, 2022, and was commercially launched on June 7, 2022[102][112]. - The company entered into a license agreement with Verity Pharma for TLANDO, receiving an initial payment of 2.5millionandanadditional2.5 million and an additional 5 million on February 1, 2024, with potential milestone payments of up to 259million[114].−ThecompanyhaslicensedTLANDOtoSPCforcommercializationinSouthKoreaandtoPharmalinkfortheGulfCooperationCouncil(GCC)region[103][106].−LPCN1154isbeingdevelopedasafast−actingoralantidepressantforpostpartumdepression,withafocusonCNSconditions[105][109].−LPCN1111,anext−generationoralTRTcandidate,completedaPhase2bstudyshowinggooddose−responserelationshipsandwaswelltolerated[120].−ThecompanyisexploringpartnershipsforLPCN1144andLPCN1148,targetingliverdiseasesandnon−cirrhoticNASH[108][109].−TheproprietaryLip′raltechnologyenhancestheabsorptionofpoorlybioavailabledrugs,improvingpatientcomplianceandsafety[110].−ThecompanyaimstosupportitslicenseesinthecommercializationofTLANDO,emphasizingtheneedforadifferentiatedoralTRToption[106].−ThecompanyisactivelyseekinglicensingagreementsforTLANDOoutsidethecurrentlicensedterritories,althoughnoagreementshavebeenfinalized[118].−ThecompanyplanstocontinuedevelopingitspipelinecandidatestargetingsignificantunmetneedsinCNSdisorders[109].−LPCN2101isbeingevaluatedforwomenwithepilepsy,withpromisingPKresultsandsafetydemonstratedinpre−clinicalandPhase1studies[131].−ThecompanyplanstoinitiateaPhase2INDopeningproof−of−conceptstudyforLPCN2101,subjecttoresourceprioritization[131].−LPCN2203isanoralcandidateformanagingessentialtremor,withsuccessfulcompletionoforalpharmacokineticsandplansforaproof−of−conceptPhase2study[144].−LPCN2401demonstrateda4.4259 million[114]. - The company has licensed TLANDO to SPC for commercialization in South Korea and to Pharmalink for the Gulf Cooperation Council (GCC) region[103][106]. - LPCN 1154 is being developed as a fast-acting oral antidepressant for postpartum depression, with a focus on CNS conditions[105][109]. - LPCN 1111, a next-generation oral TRT candidate, completed a Phase 2b study showing good dose-response relationships and was well tolerated[120]. - The company is exploring partnerships for LPCN 1144 and LPCN 1148, targeting liver diseases and non-cirrhotic NASH[108][109]. - The proprietary Lip'ral technology enhances the absorption of poorly bioavailable drugs, improving patient compliance and safety[110]. - The company aims to support its licensees in the commercialization of TLANDO, emphasizing the need for a differentiated oral TRT option[106]. - The company is actively seeking licensing agreements for TLANDO outside the current licensed territories, although no agreements have been finalized[118]. - The company plans to continue developing its pipeline candidates targeting significant unmet needs in CNS disorders[109]. - LPCN 2101 is being evaluated for women with epilepsy, with promising PK results and safety demonstrated in pre-clinical and Phase 1 studies[131]. - The company plans to initiate a Phase 2 IND opening proof-of-concept study for LPCN 2101, subject to resource prioritization[131]. - LPCN 2203 is an oral candidate for managing essential tremor, with successful completion of oral pharmacokinetics and plans for a proof-of-concept Phase 2 study[144]. - LPCN 2401 demonstrated a 4.4% increase in lean mass and a 6.7% decrease in fat mass in a Phase 2 study, with a 4.1% reduction in android fat and a 2.8% increase in bone mineral content[153]. - LPCN 1148 met its primary endpoint by increasing skeletal muscle index (L3-SMI) relative to placebo (P<.01) in patients with cirrhosis[161]. - LPCN 1148 treatment resulted in fewer observed OHE events and a longer time to the first recurrent OHE event compared to placebo[162]. - The LiFT Phase 2 clinical study for LPCN 1144 enrolled 56 biopsy-confirmed NASH male subjects, randomized into three treatment arms[168]. - LPCN 1144 treatments resulted in robust liver fat reduction assessed by MRI-PDFF after 12 weeks[170]. - LPCN 1144 treatment arms achieved statistical significance in NASH resolution with no worsening of fibrosis, showing substantial improvement in steatosis, inflammation, and ballooning[173]. - LPCN 1144 was well tolerated over 72 weeks with no observed safety signals, and liver injury markers were reduced and maintained[174]. - LPCN 1107 is being explored for partnership opportunities, with the potential to become the first oral product for the prevention of preterm birth[177]. - LPCN 1107 has shown comparable or higher average steady-state HPC levels than injectable HPC in a multi-dose PK study[179]. - The FDA granted orphan drug designation to LPCN 1107, qualifying the company for various development incentives[182]. Financial Performance - As of September 30, 2024, the company generated 49.6 million in revenue from license fees, royalties, and milestone payments since inception[184]. - Research and development expenses totaled approximately 153.5millionsinceinceptionthroughSeptember30,2024[185].−ThecompanydidnotrecognizeanyrevenueduringthethreemonthsendedSeptember30,2024,andrecordedanon−cashrevenuereversalof153.5 million since inception through September 30, 2024[185]. - The company did not recognize any revenue during the three months ended September 30, 2024, and recorded a non-cash revenue reversal of 3.1 million related to the termination of the Antares License Agreement[198]. - General and administrative expenses for the three months ended September 30, 2024, were 1,045,240,slightlyincreasingfrom1,045,240, slightly increasing from 1,042,572 in the same period of 2023[197]. - Revenue for the nine months ended September 30, 2024, was 7.7million,asignificantincreaseof7.7 million, a significant increase of 10.8 million compared to 3.1millionforthesameperiodin2023[204].−Researchanddevelopmentexpensesdecreasedby3.1 million for the same period in 2023[204]. - Research and development expenses decreased by 2.2 million to 6.3millionfortheninemonthsendedSeptember30,2024,comparedto6.3 million for the nine months ended September 30, 2024, compared to 8.5 million in 2023[203]. - General and administrative expenses increased by 358,090to358,090 to 4.1 million for the nine months ended September 30, 2024, compared to 3.8millionin2023[203].−Interestandinvestmentincomedecreasedby3.8 million in 2023[203]. - Interest and investment income decreased by 153,777 to 913,784fortheninemonthsendedSeptember30,2024,comparedto913,784 for the nine months ended September 30, 2024, compared to 1.1 million in 2023[203]. - The company had 19.8millioninunrestrictedcashandmarketablesecuritiesasofSeptember30,2024,downfrom19.8 million in unrestricted cash and marketable securities as of September 30, 2024, down from 22.0 million at December 31, 2023[210]. - The company recorded gains of approximately 138,000onwarrantliabilityforthethreemonthsendedSeptember30,2024,comparedto138,000 on warrant liability for the three months ended September 30, 2024, compared to 75,000 in 2023[202]. - The company expects to continue incurring operating losses as it advances the clinical development of multiple product candidates[209]. - No common stock warrants from the November 2019 Offering were exercised during the three or nine months ended September 30, 2024, or 2023[202]. - The company expects its existing capital resources to meet projected operating requirements through at least November 7, 2025, including ongoing clinical studies for LPCN 1154 and other product candidates[219]. - Net cash used in operating activities for the nine months ended September 30, 2024, was 2.9million,asignificantdecreasefrom2.9 million, a significant decrease from 9.8 million for the same period in 2023[224]. - Cash provided by investing activities decreased from 10.4millionintheninemonthsendedSeptember30,2023,to10.4 million in the nine months ended September 30, 2023, to 1.7 million in the same period of 2024[226]. - The company raised approximately 209,000fromfinancingactivitiesintheninemonthsendedSeptember30,2024,comparedto209,000 from financing activities in the nine months ended September 30, 2024, compared to 410,000 in the same period of 2023[227]. - Cash provided by the Verity License Agreement contributed 7.5milliontooffsetoperatingexpensesduringtheninemonthsendedSeptember30,2024[225].−Thecompanymayneedtodelayorreducethescopeofclinicalstudiesifadequatefinancingisnotobtained[222].−CapitalexpendituresfortheninemonthsendedSeptember30,2024,wereapproximately7.5 million to offset operating expenses during the nine months ended September 30, 2024[225]. - The company may need to delay or reduce the scope of clinical studies if adequate financing is not obtained[222]. - Capital expenditures for the nine months ended September 30, 2024, were approximately 80,000, compared to 4,000inthesameperiodof2023[226].−Thecompanyhasnocurrentcommitmentsoragreementsforacquisitionsorinvestmentsinbusinesses,products,ortechnologies[221].−ThecompanyisassessingtheimpactofthenewaccountingstandardsissuedinNovember2023onitsfinancialstatements[233].MarketNeedsandOpportunities−Approximately600,000womenintheU.S.areaffectedbypostpartumdepression(PPD)annually,highlightingasignificantunmetmedicalneedforeffectivetreatments[125].−Essentialtremoraffectsanestimated7millionpeopleintheU.S.,withsignificantunmetneedsintreatmentefficacyandtolerability[145].−Approximately744,000 in the same period of 2023[226]. - The company has no current commitments or agreements for acquisitions or investments in businesses, products, or technologies[221]. - The company is assessing the impact of the new accounting standards issued in November 2023 on its financial statements[233]. Market Needs and Opportunities - Approximately 600,000 women in the U.S. are affected by postpartum depression (PPD) annually, highlighting a significant unmet medical need for effective treatments[125]. - Essential tremor affects an estimated 7 million people in the U.S., with significant unmet needs in treatment efficacy and tolerability[145]. - Approximately 74% of US adults aged 20 and older are either obese or overweight, with an estimated 30% having a BMI ≥ 30 kg/m²[155]. - The total number of GLP-1 users in the U.S. is projected to reach 30 million by 2030, representing about 9% of the overall population[156]. - NASH affects approximately 20% to 30% of the U.S. population, with 15% to 20% of that group progressing to a more severe state[166]. - The economic burden of liver transplants is approximately 812,500 per transplant, with over 500,000 people living with decompensated cirrhosis in the U.S.[163]. - LPCN 2401 has the potential to improve body composition while preserving lean mass, addressing a significant unmet need in obesity management[158].